Attached files
| file | filename |
|---|---|
| EX-99.2 - POWER POINT - Riot Blockchain, Inc. | ex99_1.htm |
| EX-99.1 - SHAREHOLDER LETTER - Riot Blockchain, Inc. | appy_8k-ex99x2.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported) October 15, 2009
AspenBio Pharma,
Inc.
(Exact
name of Registrant as specified in its charter)
|
Colorado
|
001-33675
|
84-155338
|
||
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
1585
South Perry Street
Castle
Rock, Colorado
|
80104
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code:
|
(303)
794-2000
|
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01. Regulation FD Disclosure.
On
October 15, 2009, AspenBio Pharma, Inc. (the “Company”) issued a letter to its
shareholders titled — “AspenBio Pharma Progress Update.” The letter is furnished
as Exhibit 99.1 to this Form 8-K.
The
shareholders’ letter references a Company webcast that includes the power point
presentation furnished as Exhibit 99.2 to this Form 8-K. The power
point presentation is also available on the Company’s website.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibits
|
99.1
|
Shareholder
letter, dated October 15, 2009, issued by AspenBio Pharma, Inc. titled
“AspenBio Pharma Progress Update.”
|
|
99.2
|
Company
information — “Power Point Presentation” dated October
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized
|
AspenBio
Pharma, Inc.
(Registrant)
|
||||
|
October
15, 2009
|
By:
|
/s/
Jeffrey G. McGonegal
|
||
|
Name:
|
Jeffrey
G. McGonegal
|
|||
|
Title:
|
Chief
Financial Officer
|
|||